Mazandaran University of Medical Sciences   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Sari Iran (Islamic Republic of) (1986)

Organization Overview

First Clinical Trial
2013
NCT01766128
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Mazandaran University of Medical science | Mazandaran University of Medical Sciences | Mazandaran University of Medical Sciences, Mazandaran, Iran | Mazandaran University of Medical Sciences, Mazandaran, Iran. | Nasim Tabrizi | Neurology department, Mazandaran University of Medical Sciences, Sari, Iran. | Vice-Chancellor for Research, Mazandaran University of Medical Sciences

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 1)

Ischemia (Phase 3)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Multiple Sclerosis (Phase 3)

Parkinson Disease (Phase 3)

Polycystic Kidney Diseases (Phase 1)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Sclerosis (Phase 3)

Seizures (Phase 4)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 18